Table 1. Measured changes in selected ovarian reserve markers following intraovarian injection of autologous activated platelet rich plasma (PRP).
|
Patient age (yrs) |
N |
BMI |
Baseline/pre-treatment |
|
post-PRP |
tMAX1 |
p2 |
||||
|
|
|
|
d3 FSH |
d3 E2 |
AMH |
|
d3 FSH |
d3 E2 |
AMH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<42 |
48 |
23.6±5.3 |
43.1±5.9 |
91.5±15.8 |
0.21±0.5 |
|
54.3±7.3 |
53.7±8.1 |
0.32±0.08 |
4.5±0.44 |
0.030 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥42 |
134 |
23.3±4.9 |
56.1±4.1 |
63.4±6.2 |
0.17±0.03 |
|
68.4±4.7 |
53.4±7.1 |
0.21±0.04 |
4.6±0.24 |
0.009 |
BMI: body mass index (m/kg2), day #3 FSH: follicle stimulating hormone (mIU/mL), day #3 E2: estradiol (pg/mL), AMH: serum antimüllerian hormone (ng/mL). 1 mean interval between PRP injection and maximal AMH response (weeks post-PRP); 2 comparison of pre- vs. post- PRP serum AMH, by paired t-test.